CR Double-Crane Grows Profit and Net Assets Despite Flat 2025 Revenue

The latest announcement is out from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ).

China Resources Double-Crane Pharmaceutical, a Shanghai-listed subsidiary of China Resources Pharmaceutical Group, reported modest balance sheet expansion in 2025, with total assets up 1.94% and net assets attributable to shareholders rising 11.78%. The company, a key pillar of its parent’s mainland operations, continues to be prepared under PRC GAAP, and its results reflect only its standalone performance rather than that of the wider group.

For the year to 31 December 2025, Double-Crane posted revenue of RMB11.0 billion, down 1.88% year on year, but lifted net profit attributable to shareholders by 1.18%, with a stronger 9.50% increase in profit excluding extraordinary items. The board has proposed a cash dividend of RMB3.79 per 10 shares, subject to shareholder approval, signaling confidence in earnings quality even as operating cash flow declined 18.39% and return on net assets edged slightly lower to 14.86%.

The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical conglomerate with a controlling 60.24% stake in China Resources Double-Crane Pharmaceutical Co., Ltd., a Shanghai-listed drug maker in the People’s Republic of China. Through Double-Crane, the group focuses on the development, manufacturing and sale of pharmaceutical products, reinforcing its position in the mainland China healthcare market.

Average Trading Volume: 9,607,392

Technical Sentiment Signal: Sell

Current Market Cap: HK$29.28B

See more data about 3320 stock on TipRanks’ Stock Analysis page.